Biocardia announces first cross-over patient treated in cardiamp cell therapy heart failure trial

San carlos, calif., oct. 07, 2021 (globe newswire) -- biocardia®, inc.  [nasdaq: bcda] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first cross-over patient in the ongoing phase iii pivotal cardiamp® cell therapy in heart failure trial for the treatment of ischemic heart failure. a cross-over patient is one who was previously in the control group of the study, has completed follow-up, and elects to receive therapy.
BCDA Ratings Summary
BCDA Quant Ranking